P639 Tofacitinib induces clinical remission in patients with chronic pouchitis

D C de Jong,R Goetgebuer,B Müskens,A Neefjes-Borst,K Gecse,M Löwenberg,W de Jonge,W Bemelman,C Ponsioen,G D'Haens,M Duijvestein

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0769

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Up to 10% of ulcerative colitis patients and an ileal-pouch anal anastomosis will develop chronic or antibiotic refractory pouchitis. Several case reports and -series investigated the effect of tofacitinib for refractory pouchitis, but reported conflicting results(1-5). In this study, we aimed to prospectively evaluate the efficacy of tofacitinib in chronic or antibiotic refractory pouchitis using clinical and objective outcome measures. Methods We conducted a prospective single centre pilot study in which thirteen patients with chronic or antibiotic refractory pouchitis (Pouchitis Disease Activity Index (PDAI) ≥ 7, ≥2 episodes in the preceding year for which antibiotic therapy was started, or ≥4 weeks symptoms requiring maintenance therapy) were treated with tofacitinib 10mg BID for eight weeks. Clinical, biochemical, endoscopic and histologic disease activity was assessed at baseline and week 8. The primary endpoint was the proportion of patients reaching clinical remission, defined as a PDAI < 7 and a reduction of ≥ 3 points from baseline at week 8. Pouch endoscopy videos were scored by two gastroenterologists and pouch biopsies were assessed by an IBD pathologist, who were blinded to the time points and clinical outcomes. Medians and interquartile ranges were calculated, and Wilcoxon signed rank test was used to analyse changes from baseline. Results Thirteen patients (61% male, median age 34 years) were included(table 1). Three patients did not complete eight weeks of treatment due to adverse events (pyelonephritis, primo EBV infection, worsening of pouchitis), two of whom underwent an early termination endoscopy. In total, 31% achieved clinical remission (4/13) and 62% showed clinical response (8/13). Both the total PDAI score (11 (IQR 9 – 12.75) vs 8 (4.5 – 9.75), p = 0.033), and the clinical PDAI subscore (4 (3 – 4) vs 2 (0.25 – 3.75), p = 0.014) decreased significantly from baseline compared to week 8 or early withdrawal, respectively (figure 1). We did not observe a significant change in endoscopic PDAI subscore (4.5 (2 – 5.75) vs 3 (1 – 4.75), p = 0.120) or histologic subscore (3 (2 – 4) vs 2 (1 – 4), p = 0.214). Biochemical parameters did not decrease significantly compared to baseline (faecal calprotectin: 389 mg/kg (38 – 1222) vs 116 mg/kg (31 – 466), p = 0.530 (figure 2) and CRP: 1,2 mg/L (0.75 – 15.2) vs 0.95 mg/L (0.58 – 17.7), p = 0.307, (figure 3)). Conclusion In this pilot study, a clinical remission rate of 31% was achieved in patients with chronic pouchitis after eight weeks of treatment with tofacitinib. However, treatment duration of eight weeks is presumably too short to achieve biochemical, endoscopic or histologic response in these refractory patients.

gastroenterology & hepatology